A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 478-486

  Alam, Qamre ^a   Zubairalam, Mohammad ^a   Karim, Sajjad ^a   Gan, Siew H ^b   Kamal, Mohammad A ^a   Jiman Fatani, Asif ^a   Damanhouri, Ghazi A ^a   Abuzenadah, Adel M ^a   Chaudhary, Adeel G ^a   Haque, Absarul ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Alzheimer's disease; Amyloid; Chelation therapy; Insulin; Metal dysregulation; Nanodiagnostics; Nanomedicine; Nanoparticle; Nanotechnology; Targeted drug delivery; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; DEFEROXAMINE; GINKGO BILOBA EXTRACT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NANOPARTICLE; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENSERINE; PIOGLITAZONE; RANIMUSTINE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TARENFLURBIL; XALIPRODEN;

ALZHEIMER DISEASE; BIOTECHNOLOGY; BLOOD BRAIN BARRIER; DNA BARCODING; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MOLECULAR SENSOR; NANOTECHNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; ANIMAL; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; NANOTECHNOLOGY;

EID: 84904470892     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660159     Document Type: Review

References (106)

1. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 2008; 13(2): 199-223.
2. Koivisto A. Genetic components of late-onset Alzheimer's disease with special emphasis on ApoE, IL-6: CYP46: SERPINA3 and PPARg. University of Kuopio; Finland 2006.
3. Hardy J, Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
4. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
5. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-50.
6. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 2009; 9: 617-30.
7. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2008; 2(6): 1101-13.
8. Priyadarshini M, Kamal MA, Nigel H, et al. Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
9. Ott A, Stolk RP, Harskamp VF, et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 1937-42.
10. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev 2009; 14: 373-9.
11. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferatoractivated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008; 22: 1-14.
12. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges, Nat Rev Neurosci 2006; 7(1): 65-74.
13. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease 2000-2050: potential implication of treatment advances, Annu Rev Public Health 2002; 23: 213-31.
14. Ferri C, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
15. Hay JW, Ernst RL. The economic costs of Alzheimer's disease, Am J Public Health 1987; 77(9): 1169-75.
16. Yang Z. Pharmacological and Toxicological Target Organelles and Safe use of Single-walled Carbon nanotubes as Drug Carriers in Treating Alzheimer's Disease. Nanomed Nanotechnol Biol Med 2010; 6: 427-41.
17. Faraji AH, Wipf P. Nanoparticles in Cellular Drug Delivery. Bioorg Med Chem 2009; 17: 2950-62.
18. Relkin N. Screening and early diagnosis of dementia, Am J Manag Care 2000; 6(22): 1119-24.
19. Uversky VN, Kabanov AV, Lyubchenko YL. Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi. J Proteome Res 2006; 5(10): 2505-22.
20. Roco MC, Williams RS, Alivisatos P. Nanotechnology research directions, Kluwer Academic Publications: Boston 2000.
21. Subramania K, Pathakb S, Hosseinkhani H. Recent trends in diabetes treatment using nanotechnology. Digest J Nanomater Biostruct 2012; 7(1): 85-95.
22. Jabir NR, Tabrez S, Shakil S, et al. Nanotechnological Approach Towards Anticancer Research. Int J Nano Med 2012; (7): 4391-408.
23. Drexler KE. Molecular engineering: An approach to the development of general capabilities for molecular manipulation, Proc Natl Acad Sci USA 1981; 78(9): 5275-8.
24. Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta 2005; 358: 37-54.
25. Jain KK. Nanobiotechnology: Applications, Markets and Companies. Basel: Jain Pharma Biotech Public 2007; 173-83.
26. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003; 226(2): 315-36.
27. Sano M. Neuropsychological testing in the Diagnosis of Dementia. J Geriatr Psychiatry Neurol 2006; 19(3): 155-9.
28. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med 2004; 10: 34-41.
29. Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol 2005; 18(4): 218-23.
30. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticlebased detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102(7): 2273-6.
31. Nam JM, Thaxton CS, Mirkin CA. Nanoparticlebased bio-bar codes for the ultrasensitive detection of proteins. Science 2003; 301(5641): 1884-6.
32. Keating CD. Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc Natl Acad Sci USA 2005; 102(7) 2263-4.
33. Fradinger EA, Bitan G. En route to early diagnosis of Alzheimer's disease-are we there yet. Trends Biotechnol 2005; 23(11): 531-3.
34. Turner APF. Biosensors-sense and sensitivity. Science 2000; 290: 1315-7.
35. Haes AJ, Chang L, Klein WL, Van Duyne RP. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 2005; 127(7): 2264-71.
36. Haes AJ, Van Duyne RP. A nanoscale optical biosensor: sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles, J Am Chem Soc 2002; 124(35): 10596-604.
37. Kang DY, Lee JH, Oh BK, Choi JW. Ultra-sensitive immunosensor for amyloid-beta (1-42) using scanning tunneling microscopy-based electrical detection. Biosen Bioelect 2009; 24(5): 1431-6.
38. Neely A, Perry C, Varisli B, et al. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nanotechnol 2009; 3(9): 2834-40.
39. Nesterov EE, Skoch J, Hyman BT, et al. In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. Angew Chem Int Ed Engl 2005; 44(34): 5452-6.
40. Sima AA, Zhang W, Xu G, et al. A comparison of diabetic polyneuropathy in type-2 diabetic BBZDR/Wor-rat and in type 1 diabetic BB/Wor-rat. Diabetologia 2000; 43: 786-93.
41. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease later in life: longitudinal, population based study. Brit Med J 2001; 322: 1447-51.
42. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-55.
43. Harsoliya MS, Patel VM, Modasiya MJ, et al. Inter J Pharm Biol Arch 2012; 3(2): 255-61.
44. ConnellMc HM. The cytosensor microphysiometer: biological applications of silicon technology. Sci Live J 1992; 257(507): 1906-12.
45. Microphysiometer using multiwall carbon nanotubes enable constant realtime monitoring of microliters of insulin [Accessed on Apr 18, 2008]. Available from: http://nextbigfuture.com/2008/04/microphysiom eter-using-multiwall carbon.html
46. Erin M. Implantable glucose sensors. Health Tech Zone Med Feat Art 2010; 2: 2-6.
47. Gordon N, Sagman U. Nanomedicine Taxonomy. Can Nano Busin Alliance 2003; 1-28.
48. Jasjeet Kaur SAC, Sihem DA, Javed AB, et al. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Contr Release 2011; 152: 208-31.
49. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30(6): 1204-15.
50. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43(8): 1609-11.
51. Al-Jafari AA, Kamal MA, Greig NH, Alhomida AS, Perry E. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: Phenserine. Biochem Biophys Res Comm 1998; 248(1): 180-5.
52. Al-Jafari AA, Kamal MA, Alhomida AS, Greig NH. Kinetics of rat brain acetylcholinesterase inhibition by two experimental Alzheimer's disease drugs, phenserine and tolserine. J Biochem Mol Biol Biophys 2000; 4: 323-35.
53. Kamal MA, Greig NH, Al-Jafari AA. A new, simple and economical approach to analyse the inhibition kinetics of acetylcholinesterase using tolserine. Em Med J 2002 20(3): 333-7.
54. Kamal MA, Greig NH, Alhomida AS, Al-Jafari AA. Kinetics of human acetylcholinesterase inhibition by novel experimental Alzheimer therapeutic agent, tolserine. Biochem Pharmacol 2000; 60(4): 561-70.
55. Kamal MA, Al-Jafari AA, Qian-Sheng Y, Greig NH. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. Biochem Biophys Acta 2006; 1760: 200-6.
56. Batool S, Nawaz MS, Greig NH, Rehan M, Kamal MA. Molecular Interaction study of N1-p-fluorobenzyl-cymserine with TNF-α, p38 kinase and JNK kinase. Antiinflamm Antiallergy Agents Med Chem 2013; 12(2): 129-35.
57. Kamal MA, Qu X, Yu QS, et al. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Trans 2008; 115(6): 889-98.
58. Kamal MA, Klein P, Luo W, et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res 2008; 33(5): 745-53.
59. Kamal MA, Yu QS, Holloway HW, et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006; 10(1): 43-51.
60. Greig NH, Utsuki T, Yu QS, et al. Dissociation between the potent β-amyloid protein pathway inhibition and cholinergic actions of the Alzheimer drug candidates phenserine and cymserine. In: Advances in Alzheimer's and Parkinson's Disease: Insights, Progress, and Perspectives, (Eds. A. Fisher M. Memo F. Stocchi, and I.Hanin): Springer Science + Business Media, USA 2008; pp. 445-62.
61. Liu G, Men P, Perry G, Smith MA. Nanoparticle and Iron Chelators as a Potential Novel Alzheimer Therapy. Methods Mol Biol 2010; 610: 123-44.
62. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009; 7: 7.
63. Iqbal K, Grundke-Iqbal I. Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 2007; 64: 2234-44.
64. Malhotra M, Prakash S. Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles. Curr Nanosci 2009; 7: 81-93.
65. Zhuang Z, Kung M, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001; 44: 1905-14.
66. Gutman R, Peacock G, Lu D. Targeted drug delivery for brain cancer treatment. J Control Release 2000; 65: 31-41.
67. Huang X, Cuajungco M, Atwood C. Cu (II) potentiation of Alzheimer AB neurotoxicity. J Biol Chem 1999; 274: 37111-6.
68. Ritchie C, Bush A, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydorxyquin (clioquinol) targeting AB amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003; 60: 1685-91.
69. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed 2008; 3(2): 133-49.
70. LaVan DA, McGuire T, Langer R. Small scale systems for in vivo drug delivery. Nat Biotechnol 2003; 21: 1184-91.
71. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 2001; 49: 289-99.
72. Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clin Ther 2001; 23: 13-24.
73. Prasad KN, Hovland AR, Cole WC, et al. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 2000; 23: 2-13.
74. Webber KM, Bowen R, Casadesus G, et al. Gonadotropins and Alzheimer's disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiol Exp 2004; 64: 113-8.
75. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61(1): 82-8.
76. Schmitt B, Bernhardt T, Moeller HJ, Heuser I, Frolich L. Combination therapy in Alzheimer's disease: a review of current Evidence. CNS Drugs 2004; 18: 827-44.
77. Prasad KN, Hovland AR, Cole WC, et al. Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol 2000; 23: 2-13.
78. Perry G, Castellani RJ, Hirai KM, Smith A. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1998; 1: 45-55.
79. Casadesus G, Smith MA, Zhu X, et al. Alzheimer's disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 2004; 6: 165-9.
80. Gutteridge JM. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann NY Acad Sci 1994; 738: 201-13.
81. Evans PH. Free radicals in brain metabolism and pathology. Br Med Bull 1993; 49: 577-87.
82. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 20009: 20: 292-304.
83. Richardson DR, Ponka P. Development of iron chelators to Treat iron overload disease and their use as experimental tools toprobe intracellular iron metabolism. Am J Hematol 1998; 58: 299-305.
84. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964; 119: 758-68.
85. Hider RC, Hall AD. Clinically useful chelators of tripositiveElements. Prog Med Chem 1991; 28: 41-173.
86. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621-9.
87. Markesbery WR, Ehmann WD. Oxidative stress in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, Sisodia SS. editors. Alzheimer Disease. Philadelphia: Lippincott Williams & Wilkins 1999; pp. 401-414.
88. Kong S, Liochev S, Fridovich I. Aluminum (III) facilitates the Oxidation of NADH by the superoxide anion, Free Radic. Biol Med 1992; 13: 79-81.
89. Liub G, Matthew R, Garretta MP, et al. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta 2005; 1741: 246-52.
90. Kasuga M. Insulin resistance and pancreatic beta cell failure. J Clin Invest 2006; 116: 1756-60.
91. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-9.
92. Monnier L, Colette C. Glycemic variability. Should we and can we prevent it? Diabetes Care 2008; 31: 150-4.
93. Tuomilehto J, Lidstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
94. Mahmud M. American Diabetes Association Standard of medical care in diabetes. Diabetes Care 2009; 32: 13-61.
95. Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract 2008; 14: 625-38.
96. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
97. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
98. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007; 99: 51-67.
99. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
100. Modi P. Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. Curr Drug Discov Technol 2007; 4(1): 39-47.
101. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol 2003; 10: 128-36.
102. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-99.
103. Ho MP, Rumsfeld JS, Masoudi FA. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-41.
104. Satheesh B. Nanoparticles in the treatment of diabetes. Pharm Info 2011; 5: 11.
105. Insulin Nanopump for Accurate Drug Delivery. [Accessed Aug 15, 2008]. Available from: http://thefutureofthings.com/news/1286/insulinnanopump-for-accuratedrug-delivery.html
106. Iqbal A, Ahmad I, Khalid MH, et al. Nanoneurotoxicity to nanoneuroprotection using biological & computational approaches. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013; 31(3): 256-84.